RYTM / Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q4 2021 Results - Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. is focused on developing treatments for orphan obesity syndromes caused by defects in the MC4R pathway. Their product Imc more_horizontal

BOSTON, July 18, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transf more_horizontal

Today, we check back in on Rhythm Pharmaceuticals, Inc., an entrant into the fast-growing weight management medicine space. The company is simultaneou more_horizontal

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q1 2023 Earnings Conference Call May 2, 2023 8:00 AM ET Company Participants David Connolly - Executive Di more_horizontal

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 8.54% and 24.56%, respectively, for the quarter ended December 2022. D more_horizontal

Rhythm Pharmaceuticals is planning to get approvals for setmelanotide in an incremental fashion. Each new approval in a rare disease will add to the t more_horizontal

Here's why our roundtable is bullish on Shockwave Medical, Axsome Therapeutics, and Rhythm Pharmaceuticals. more_horizontal

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2022 Results Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants David Connolly - I more_horizontal